Castle Biosciences Swings to Q1 Loss as Revenue Gain Beats Street View; Sets Full-Year Revenue Outlook
05:04 PM EDT, 05/10/2021 (MT Newswires) -- Castle Biosciences (CSTL) late Monday reported a Q1 net loss of $0.17 per share, reversing from a profit of $0.03 per share in the year-ago quarter.
Analysts polled by Capital IQ were expecting a loss of $0.19 per share.
Revenue for the quarter ended March 31 was $22.8 million, compared with $17.4 million in the year-ago period.
Analysts were expecting revenue of $16.66 million.
The company said it expects full-year revenue of $80 million to $83 million, compared with average analyst estimate of $79.8 million.
Shares were up marginally in the after-hours session.
Price: 55.00, Change: +0.22, Percent Change: +0.40